A select set of opioid ligands induce up-regulation by promoting the maturation and stability of the rat κ-opioid receptor in human embryonic kidney 293 cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 614-625

  Wannemacher, Kenneth M ^a   Yadav, Prem N ^a   Howells, Richard D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALOXONE; BREFELDIN A; CELL SURFACE RECEPTOR; CYCLAZOCINE; CYCLOHEXIMIDE; DIPRENORPHINE; DYNORPHIN[1-13]; ETORPHINE; GLYCOSIDASE; KAPPA OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; NALTREXONE; SALVINORIN A;

ARTICLE; CELL LYSATE; CELL MATURATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; KIDNEY CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; BENZENEACETAMIDES; BREFELDIN A; CELLS, CULTURED; CYCLOHEXIMIDE; DIPRENORPHINE; HUMANS; LIGANDS; NALOXONE; NALTREXONE; PYRROLIDINES; RATS; RECEPTORS, OPIOID, KAPPA; RNA, MESSENGER; TRANSFECTION; UP-REGULATION;

EID: 35549001400     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125500     Document Type: Article

References (35)

1. Bhavanandan V and Katlic A (1979) The interaction of wheat germ agglutinin with sialoglycoproteins. J Biol Chem 254:4000-4007.
2. Castelli MP, Melis M, Mameli M, Fadda P, Diaz G, and Gessa GL (1997) Chronic morphine and naltrexone fail to modify μ-opioid receptor mRNA levels in the rat brain. Mol Brain Res 45:149-153.
3. Chaipatikul V, Erickson-Herbrandson LJ, Loh HH, and Law PY (2003) Rescuing the traffic-deficient mutants of rat μ-opioid receptors with hydrophobic ligands. Mol Pharmacol 64:32-41.
4. Chaturvedi K, Bandari P, Chinen N, and Howells RD (2001) Proteasome involvement in agonist-induced down regulation of μ and δ opioid receptors. J Biol Chem 276:12345-12355.
5. Chege NW and Pfeffer SR (1990) Compartmentation of the Golgi complex: brefeldin A distinguishes trans-Golgi cisternae from the trans-Golgi network. J Cell Biol 111:893-899.
6. Chen Y, Chen C, Wang Y, and Liu-Chen LY (2006) Ligands regulate cell surface level of the human κ opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists. J Pharmacol Exp Ther 319:765-775.
7. Ellgaard L and Helenius A (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4:181-191.
8. Jenab S, Kest B, and Inturrisi CE (1995) Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment. Brain Res 691:69-75.
9. Jordan BA, Cvejic S, and Devi LA (2000) Kappa opioid receptor endocytosis by dynorphin peptides. DNA Cell Biol 19:19-27.
10. Lahti R and Collins R (1978) Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur J Pharmacol 51:185-186.
11. Latronico AC and Segaloff DL (1999) Naturally occurring mutations of the luteinizing hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors. Am J Hum Genet 65:949-958.
12. Leanos-Miranda A, Ulloa-Aguirre A, Janovick JA, and Conn PM (2005) In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. J Clin Endocrinol Metab 90:3001-3008.
13. Lesscher HM, Bailey A, Burbach JP, Van Ree JM, Kitchen I, and Gerrits MA (2003) Receptor-selective changes in mu-, delta-, and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci 17:1006-1012.
14. Li J, Chen C, Huang P, and Liu-Chen L (2001) Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat μ-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 60:1064-1075.
15. Lippincott-Schwartz J, Yuan LC, Bonifacino JS, and Klausner RD (1989) Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 56:801-813.
16. Lippincott-Schwartz J, Yuan LC, Tipper C, Amherdt M, Orci L, and Klausner RD (1991) Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell 67:601-616.
17. Magnan J, Paterson SJ, Tavani A, and Kosterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn Schmiedebergs Arch Pharmacol 319:197-205.
18. Marinova Z, Vukojevic V, Surcheva S, Yakovleva T, Cebers G, Pasikova N, Usynin I, Hugonin L, Fang W, Hallberg M, et al. (2005) Translocation of dynorphin neuropeptides across the plasma membrane. J Biol Chem 280:26360-26370.
19. McQuay H (1999) Opioids in pain management. Lancet 353:2229-2232.
20. Morello J-P, Salahpour A, Laperriere A, Bernier V, Arthus M-F, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, et al. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105:887-895.
21. Morris BJ, Millan MJ, and Herz A (1988) Antagonist-induced opioid receptor upregulation: II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography. J Pharmacol Exp Ther 247:729-736.
22. Niu T-K, Pfeifer AC, Lippincott-Schwartz J, and Jackson CL (2005) Dynamics of GBF1, a brefeldin A-sensitive Arf1 exchange factor at the Golgi. Mol Biol Cell 16:1213-1222.
23. Oksche A and Rosenthal W (1998) The molecular basis of nephrogenic diabetes insipidus. J Mol Med 76:327-337.
24. Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP, and Bouvier M (2002) Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J 21:1628-1637.
25. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR (2000) Rapid degradation of a large fraction of newly synthesized proteins by the proteasome. Nature 404:770-774.
26. Sung C-H, Schneider BG, Agarwal N, Papermaster DS, and Nathans J (1991) Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 88:8840-8844.
27. Tang AH and Collins RJ (1978) Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat. Eur J Pharmacol 47:473-474.
28. Tartakoff AM and Vassalli P (1983) Lectin-binding sites as markers of Golgi subcompartments: proximal-to-distal maturation of oligosaccharides. J Cell Biol 97:1243-1248.
29. Thomas PJ, Qu B, and Pederson PI (1995) Defective protein folding as a basis of human disease. Trends Biochem Sci 20:456-459.
30. Unterwald EM, Rubenfeld JM, Imai Y, Wang JB, Uhl GR, and Kreek MJ (1995) Chronic opioid antagonist administration up-regulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol Brain Res 33:351-355.
31. Unterwald EM and Howells RD (2008) Up-regulation of opioid receptors, in Opioid Receptors and Antagonists: From Bench to Clinic: Contemporary Neuroscience Series (Dean RL III, Bilsky EJ, and Negus SS III eds), Humana Press, Totowa, NJ, in press.
32. Valentino RJ, Katz JL, Medzhiradsky F, and Woods JH (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32:2887-2896.
33. Welch WJ and Howard M (2000) Antagonists to the rescue. J Clin Invest 105:853-854.
34. Yadav PN, Chaturvedi K, and Howells RD (2007) Inhibition of agonist-induced down regulation of the δ-opioid receptor with a proteasome inhibitor attenuates opioid tolerance in human embryonic kidney 293 cells. J Pharmacol Exp Ther 320:1-9.
35. Zhang F, Li J, Li J-G, and Liu-Chen L-Y (2002) (-)U50,488H [(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) -cyclohexyl]benzeneacetamide] induces internalization and down-regulation of the human, but not the rat, κ-opioid receptor: structural basis for the differential regulation. J Pharmacol Exp Ther 302:1184-1192.